Explore

Companies

Drugs

About·Data Management·Terms·Privacy

Stay informed

© 2026 VivoSeq. All rights reserved.

XC001

Phase 2Small molecule

XXyloCor Therapeutics, Inc.

1

Indications

1

Total Trials

1

Active Trials

0

Competitors

Pipeline

Status by Indication[3][1]

Indication

AngiogenesisNot yet recruiting

AngiogenesisPhase 2

Not yet recruiting

Timeline

Expected Milestones

Q2 2027

Phase 2Not yet recruiting

Angiogenesis

NCT07118449

Clinical

Trials by Indication[1]

Angiogenesis1 trial

Epicardial Delivery of XC001 Gene Therapy to Promote Angiogenesis in CAD Patients Undergoing Treatment With CABG

Not yet recruiting·XXyloCor Therapeutics, Inc.·Phase 2·NCT07118449·116 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for XC001. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — XC001 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for XC001. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — XyloCor Therapeutics, Inc. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: XXyloCor Therapeutics, Inc.

Related News